HELIGENICS INC
GigaAssay platform for high-throughput functional screening of protein variant libraries
- Sector
- Biotech
- Total capital
- $2M
- Federal grants
- $2M
- 3 awards · 2023–2026
- Rank in peer group#3 of 37
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 21 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · High Content Screening for Bifunctional Chimera Biologics$801K
- Federal grantHealth and Human S · Phase II · High Content Screening for Bifunctional Chimera Biologics$808K
- Federal grantHealth and Human S · Phase I · High-throughput functional analysis and clinical relevance of all possible variants of a gene$399K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 37 peers
Line = medianBiotech · Platform
- Federal grants#3 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Martin R SchillerResearcherExecutive OfficerLinked by $399K in grants as PI
- Lawrence John LoomisExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 21- PendingMethod for Evaluating Clinical Relevance of Genetic VarianceUSPTOApplication 19049231
- PendingHigh-Throughput Cellular Molecular Function Assay System and MethodUSPTOApplication 18405052
- PendingMethod For Producing And Screening Multi-functional Chimeric Biologic LibrariesUSPTOApplication PCTUS2024038561
Show all 21 patent records
- Method for Evaluating Clinical Relevance of Genetic VarianceAug 28, 2025 · Application 19049231Pending
- High-Throughput Cellular Molecular Function Assay System and MethodOct 17, 2024 · Application 18405052Pending
- Method For Producing And Screening Multi-functional Chimeric Biologic LibrariesApplication PCTUS2024038561Pending
- Mutation Effect And Activity Profile Mapping System And MethodApplication PCTUS2024023134Pending
- Glycosylated Non-naturally Occurring InterferonsApplication 63566081Pending
- Non-Naturally Occurring InterferonsApplication 63537946Pending
- Non-Naturally Occurring InterferonsApplication 63537905Pending
- Method For Evaluating Clinical Relevance Of Genetic VarianceApplication PCTUS2023071962Pending
- Method for Producing and Screening Multi-Functional Chimeric Biologic LibrariesApplication 63528211Pending
- Method for Producing and Screening Multi-Functional Chimeric Biologic LibrariesApplication 63527490Pending
- Dominant Negative Variants And Dominant Negative Multi-gene Chimera Drug Leads Screening System And MethodApplication 63498831Pending
- Mutation Effect And Activity Profile Mapping System And MethodApplication 63494228Pending
- Method For Evaluating Clinical Relevance Of Genetic VarianceApplication 63375369Pending
- Methods For HER2 Tyrosine Kinase Domain Activation Of PHOSPHO-HER2Application 63370837Pending
- High-throughput Cellular Molecular Function Assay System And MethodApplication PCTUS2022073427Pending
- Methods For Identification And Characterization Of SARS-COV-2 VariantsApplication 63325000Pending
- High-throughput Cellular Molecular Function Assay System And MethodApplication 63218429Pending
- Method For Producing And Screening Multi-functional Chimeric Biologic LibrariesApplication 19502851Pending
- Glycosylated Engineered Interferon Beta ProteinsApplication PCTUS2025020102Pending
- Engineered Interferon-beta ProteinsApplication 19518502Pending
- Engineered Interferon-beta ProteinsApplication PCTUS2024046509Pending
Related companies, and why
- CLARAMETYX BIOSCIENCES, INCSimilar federal contract value in Biotech · null in contracts
- KALA BIO, Inc.Similar federal contract value in Biotech · null in contracts
- Provenance Group, Inc.Similar federal contract value in Biotech · null in contracts
- Dayi Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Rise Therapeutics, LLCSimilar federal contract value in Biotech · null in contracts
- Faraday BiosciencesSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .